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ABSTRACT 
A Simple, precise, accurate and economical spectrophotometric method was developed and validated for simultaneous estimation of 
Lamivudine (LAM) and Tenofovir disoproxil fumarate (TDF) in combined  dosage form. In simultaneous equation method, LAM and TDF were 
quantified using their absorptivity values at selected wavelengths, viz., 276nm and 260nm respectively in water solvent system. LAM and TDF 
obeyed Beer’s law in the concentration range of 5-25μg/ml. Different analytical parameters such as linearity, precision, accuracy, limit of 
detection (LOD) and limit of quantification (LOQ) were determined as per ICH guidelines (Q2A & Q2B). % Recovery for both the drugs were in 
the range of 98.31-98.94%  indicating excellent accuracy. The methods were precise, with a relative standard deviation of less than 2% for both 
drugs. The simultaneous equation method permits simple, rapid and direct determination of LAM and TDF in commercially available combined 
dosage form without previous separations and can therefore be used for routine analysis. 
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INTRODUCTION 
Tenofovir disoproxil fumarate(TDF) (a prodrug of tenofovir) 
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy} 
methyl)phosphonic acid), belongs to a class of antiretroviral 
drugs known as nucleotide analogue reverse transcriptase 
inhibitors (nRTIs), which block reverse transcriptase, an 
enzyme crucial to viral production in HIV-infected people. In 
vivo TDF is converted to tenofovir, an acyclic nucleoside 
phosphonate (nucleotide) analog of adenosine 5’-
monophosphate [1]. Lamivudine (LAM) (4-amino-1-[(2R, 
5S)-2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]-1, 2- 
dihydropyrimidin-2-one) is nucleoside analogues with a 
structure that consists of a pyrimidine base which is N-
substituted at the 1-position with a 3’-thia derivative (1,3-
oxazolidine) of the ribose moiety that is characteristic of 
nucleosides. It is reverse trascriptase inhibitor and 
zalcitabine analog in which a sulfur atom replaces the 3’ 
carbon of the pentose ring. It is used to treat HIV-1 and 
hepatitis B (HBV). This compound belongs to the class of 
organic compounds known as 3’-thia pyrimidine nucleosides 
[2]. Both the drugs are marketed as combined dose tablet 
formulation in the ratio of 300:300mg LAM: TDF. Literature 
survey reveals that TDF is estimated individually by UV [3], 
derivative-HPLC [4], Plasma RP-HPLC [5, 6] and Plasma 
LC/MS/MS [7-9] methods. Similarly for LAM, HPLC [10], 
Titrimetry [11, 12] and HPLC in plasma [13-15] were 
reported. The purpose of this study was to develop simple, 
rapid, precise and accurate UV method for the simultaneous 
estimation of TDF and LAM in pure and in combined tablet 
dosage form by Simultaneous equation method and validate 
as per International Conference on Harmonization (ICH) 
guidelines. 
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Figure 1 Chemical structure of (A) Tenofovir disoproxil 
fumarate (B) Lamivudine 
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MATERIALS AND METHODS 
Reagents and chemicals 
Working standards of pharmaceutical grade LAM and TDF 
were obtained as gift samples from Scan Research 
Laboratories, Bhopal. The tablet dosage form, TENVIR - L, 
manufactured by Cipla Limited, Mumbai, India (Label Claim: 
LAM 300 mg and TDF 300 mg), was procured from the local 
pharmacy. Milli Q water was used throughout the study. All 
the chemicals and reagents used were of analytical grade and 
purchased from Qualigens Fine Chemicals, Mumbai, India. 
Instrument 
In UV-spectrophotometric method, Labindia model-3000+ 
series were used, which is a wavelength accuracy ±1 nm, 
with 1cm quartz cells. 
Method development 
Standard stock solution (Stock-A) 
Standard stock solutions were prepared by dissolving 
separately 100 mg of each drug in 80ml Milli Q water in 100 
ml volumetric flask and the flask was sonicated for about 10 
min to solubilizing the drug and the volume was made up 
to the mark with Milli Q water to get a concentration of 1000 
µg/ml (Stock-A) for both drugs. 
Sub Stock Solution (Stock-B) 
Aliquots of 2.5 ml withdrawn with help of pipette from 
standard stock solution A of LAM and TDF and transferred 
into 25 ml volumetric flask separately and diluted up to 25 
ml with Milli Q water that gave concentration of 100µg/ml 
(Stock-B). 
Determination of λmax 
Standard solutions of 50g/ml of LAM and 2g/ml TDF were 
prepared separately from respective sub-stock solutions. 
Both the solutions were scanned in the spectrum mode from 
200 nm to 400 nm. The maximum absorbance of LAM and 
TDF were observed at 276.0 nm and 260.0 nm, respectively. 
They were scanned in the wavelength range of 200-400 nm 
and the overlain spectrum was obtained (Figure 2-4). 
 
Figure 2 Determination of λmax of LAM 
 
Figure 3 Determination of λmax of TDF 
 
Figure 4 overlay spectra of LAM and TDF 
Preparation of calibration curve 
From the standard stock solution of each drug, appropriate 
aliquots were pipette out into a series of 10 ml volumetric 
flasks. The volume was made up to the mark with Milli Q 
water to get a set of solutions having a concentration range 
of 5-25µg/ml for both drugs. Triplicate dilutions of each drug 
solutions were prepared separately. The prepared working 
solutions of LAM and TDF were scanned 276 nm and 260 nm, 
respectively. The absorbance’s were recorded and were 
plotted against the concentrations to obtain their respective 
calibration curves.  
Simultaneous equation method (Vierordt’s) 
The overlain spectra also showed isoabsorptive points at 269 
nm. Due to difference in absorbance maxima and having no 
interference with each other so both drug can be 
simultaneously estimated by simultaneous equation method.  
Simultaneous equation method is based on the absorption of 
drugs (X and Y) at the wavelength maximum of the other. 
Two wavelengths selected for the method are 276.0 nm and 
260.0 nm that are λmax of LAM and TDF respectively. The 
absorbances were measured at the selected wavelengths and 
absorptivities (A1%, 1cm) for both the drugs at both 
wavelengths were determined as mean of five independent 
determinations. Concentrations in the sample were obtained 
by using following equations.  
 
Where, A1 and A2 are absorbances of mixture at 276.0 nm and 
260.0 nm respectively, ax1 and ax2 are absorptivities of LAM 
at λ1 (276.0 i.e. λmax of LAM) and λ2 (260.0 i.e. λmax of TDF) 
respectively and ay1 and ay2 are absorptivities of TDF at λ1 
and λ2 respectively. CTDF and CLAM are concentrations of LAM 
and TDF respectively. Figure 4 represent the overlain 
spectra of both the drugs in 1:1 ratio and the criteria for 
obtaining maximum precision[i.e. absorbance ratio 
(A2/A1)/ax2/ax1 and ay2/ay1] by this method were 
calculated
 
and found to be outside the range of 0.1-2.0 
which is satisfied for both the LAM and TDF [16].  
Methods validation  
Validation of the method was carried out in accordance with 
the International Conference on Harmonization Q2A & Q2B 
guidelines 2005 [17].  
 
Bhadauria et al                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):1156-1159 
ISSN: 2250-1177                                                                                  [1158]                                                                                 CODEN (USA): JDDTAO 
Linearity 
The linearity of analytical method was carried out to check 
its ability to elicit test results that are proportional to the 
concentration of analyte in sample within a given range. 
Different levels of standard solutions were prepared and 
estimate into the UV and the results was recorded. The 
results of linearity are reported in Table 1 and Figure 5 & 6. 
Accuracy 
The validity and reliability of proposed methods were 
assessed by recovery studies by using standard addition 
method. The recovery of added standards (80%, 100% and 
120%) was found at three replicate and three concentrations 
level. The value of % means just close to 100, SD and % RSD 
are less than 2 indicate the accuracy of method. Result of 
recovery study shown in Table 2. 
Precision 
Precision was determined by repeatability and Intermediate 
precision (Day to day, Analyst-to-Analyst) of drug. 
Repeatability result indicates the precision under the same 
operating condition over short interval time. The 
intermediate precision study is expressed within laboratory 
variation on different days and analyst to analyst variation 
by different analyst. The value of SD and %RSD are less than 
2 indicate the precision of method. Result of precision shown 
in Table 3. 
Detection Limit and Quantitation Limit 
The LOD and LOQ of developed method were calculated 
based on the standard deviation of response and slope of the 
linearity curve Table 4.  
Assay of Tablet Formulation 
Mixed Blends of LAM and TDF were weighed and ground to 
a fine powder; amount equal to 100mg of TDF was taken in 
100ml volumetric flask. The present in this amount of 
marketed tablets (TENVIR-L tablet, Cipla) was 300mg LAM. 
Then 50ml of Milli Q water was added and the flask was 
sonicated for about 10 min to solubilizing the drug present 
in tablet formulation and the volume was made up to the 
mark with Milli Q water. After sonication filtration was done 
through Whatman filter paper No. 41. Filtrate was 
collected and further diluted with buffer to get the final 
concentrations of both drugs in the working range. The 
absorbance of final dilutions was observed at selected 
wavelengths and the concentrations were obtained from 
simultaneous equation method. The procedure was repeated 
for five times Table 5. 
RESULTS AND DISCUSSION 
Method development by UV-Spectrophotometer is cost 
effective and time saving as compared to HPLC method of 
analysis [18].  Thus, for estimation of routine sample of drugs 
simple, rapid, sensitive and accurate analytical UV methods 
were utilized which reduces unnecessary tedious sample 
preparations and use of costly materials. To develop suitable 
methods of analysis, various solvents were studied. Based on 
sensitivity of the method , Milli Q water was selected as a 
solvent for the methods. Overlain spectra (Figure 4) shows 
that at λmax of LAM (276 nm) interference of TDF and at λmax 
of TDF (260nm) interference of LAM occurs which suggested 
development of simultaneous equation method. The 
optimized methods showed good reproducibility and mean 
recovery with 99.666± 0.039 (LAM), 98.311±0.145 (TDF) 
and 98.37±0.921 (LAM), 98.70±0.513 (TDF) respectively. 
Result of precision at different levels was found to be within 
acceptable limits (RSD < 2). Thus, the method provides a 
simple, convenient, rapid and accurate way to determine 
LAM and TDF simultaneously. 
 
Figure 5: Calibration Curve of LAM 
 
Figure 6: Calibration Curve of TDF 
Table 1 Results of Linearity of LAM and TDF 
PARAMETER LAM TDF 
Concentration (μg/ml) 5-25 5-25 
Correlation Coefficient (r2)* 0.999 0.999 
Slope (m)* 0.028 0.020 
Intercept (c)* 0.003 -0.000 
*value of five replicate 
Table 2 Results of Recovery Study 
% LEVEL % MEAN±SD* 
 LAM TDF 
80% 98.30±1.125 98.94±0.798 
100% 98.37±0.921 98.70±0.513 
120% 98.31±1.338 98.33±1.075 
* Value of three replicate and five concentrations. 
Table 3 Results of Precision 
PARAMETER 
% MEAN±SD* 
LAM TDF 
Repeatability 98.719±0.166 98.887±0.143 
                                                       Intermediate precision 
Day to day  99.075±0.146 99.183±0.098 
Analyst-to-Analyst  98.847±0.143 99.556±0.093 
Reproducibility 99.666± 0.039 98.311±0.145 
* Value of five replicate and five concentrations 
Table 4 LOD and LOQ OF LAM and TDF 
Name LOD (g/ml) LOQ (g/ml) 
LAM 0.85 2.35 
TDF 1.12 3.31 
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Table 5 Assay of Tablet Formulation 
 % Conc. Found 
LAM   TDF 
Mean 97.75 98.47 
S.D. 1.480 1.304 
% RSD 1.514 1.324 
*Average of three replicate 
CONCLUSION 
A new, simple, sensitive and economical UV 
spectrophotometric method was developed for the 
simultaneous estimation of LAM and TDF in their tablet 
formulation. The standard deviation, % RSD for the methods 
are low, reflecting a high degree of precision of the methods. 
The results of the recovery studies performed show the high 
degree of accuracy of the proposed methods. Vierordt’s 
method has the advantage of being simple, economic, rapid 
and subsequently not required sophisticated technique, 
instrument and costly solvents. Thus, the proposed methods 
can be successfully applied for determination and dissolution 
testing of LAM and TDF in commercial tablet formulations.  
ACKNOWLEDGEMENT 
The authors are very thankful to Principal and Management 
of Jaipur College of Pharmacy,Jaipur and Scan Research 
Laboratories,Bhopal (M.P.) for  providing necessary facilities 
to carry out research work. 
REFERENCES 
1. http://www.drugbank.ca/drugs/DB00222  
2. http://www.drugbank.ca/drugs/DB01132 
3. Shirkhedkar A A, Bhirud C H, Surana S J (2009) Application of 
UVSpectrophotometric Methods for Estimation of Tenofovir 
Disoproxil Fumarate in Tablets. Pak J Pharm Sci 22(1): 27-29. 
4. Sparidans R W, Crommentuyn K M, Schellens J H, Beijnen J H 
(2003) Liquid- Chromatography assay for the antiviral 
nucleotide analogue tenofovir in plasma using derivitization 
with chloroacetaldehyde. J Chromatogr B 791: 227-33. 
5. Sentenac S, Fernandez C, Thuillier A, Lechat P and Aymard G 
(2003) Sensitive determination of tenofovir in human plasma 
samples using reversed-phase liquidchromatography. J 
Chromatogr B 793(2): 317-24. 
6. Kandagal P B, Manjunatha D H, Seetharamappa J and Kalanur S 
S (2008) RP-HPLC method for the determination of tenofovir 
in pharmaceutical formulations and spiked human plasma. 
Anal Lett 41(4): 561-70. 
7. Delahunty T, Bushman L, Fletcher C V (2006) Sensitive assay 
for determining plasma tenofovir concentrations by 
LC/MS/MS. J Chromatogr B 830: 6-12. 
8. Massaki T, Yuichi K, Naoya O, Atsushi H, Kazuhide B, 
Tsuguhiro K (2007) Determination of plasma tenofovir 
concentration using a conventional LC-MS method. Biol Pharm 
Bull 30: 1784-86. 
9. King T, Bushman L, Kiser J, Anderson P L, Michelle R, 
Delahunty T and Fletcher C V (2006) Liquid chromatography-
tandem mass spectrometric determination of tenofovir-
diphosphate in human peripheral blood mononuclear cells. J 
Chromato B 843(2,7): 147-56. 
10. Marc Schuman, Serge Schneider,Christine Omes, Robert 
Wennig, Leon Fundira, Jean- Claude Tayari and Vic Arendt 
(2005) HPLC analysis of generic antiretroviral drugs  
purchased in Rwanda. Bull Soc Sci Med 3: 317 – 325. 
11. Basavaiah K and Somashekar B C (2006) Titrimetric and 
Spectrophotometric methods for the assay of Lamivudine in 
Pharmaceuticals. J Sci Ind Res 65: 349 – 354. 
12. Basavaiah K, Somashekar B C and Ramakrishna V (2007) 
Rapid titrimetric and spectrophotometric assay methods for 
the determination of lamivudine in Pharmaceuticals using 
iodate and two dyes. J Anal Chem 62 (6): 542 – 548. 
13. Gholamreza Bahrami, Shahla Mirzaeei, Amir Kiani and 
Bahareh Mohammadi (2005) High-performance liquid 
chromatographic determination of lamivudine in human 
serum using liquid–liquid extraction; application to 
pharmacokinetic studies. J Chromatogr B 823 (2): 213 – 217. 
14. Sibel A, OzkanBengi and Uslu (2002) Rapid HPLC Assay for 
Lamivudine in Pharmaceuticals and Human Serum. J Liq 
Chromatogr and Rel Tech 25 (9): 1447 – 1456. 
15. Eunice Kazue Kano, Cristina Helena dos Reis Serra, Eunice 
Emiko Mori Koono and Simone Schramm (2006) 
Determination of lamivudine in human plasma by HPLC and 
its use in bioequivalence studies. J Pharm Biomed Anal 4 (3): 
761 – 765. 
16. Beckett AH, Stanlake JB. Practical Pharmaceutical Chemistry, 
fourth ed., part 2. CBS Publishers and Distributors, New Delhi 
1997. 
17. ICH Guidelines: Validation of Analytical Procedures: Text and 
Methodology Q2 (B), 2005. 
18. Laxman R, Acharya A, Jain V, Bhardwaj S, Jain D. Development 
and validation of RP-HPLC and ultraviolet spectrophotometric 
methods simultaneous determination of spironolactone and 
torsemide in pharmaceutical dosage form. Int J Res 
Ayurveda Pharm 2010; 1(2):459-467 
 
 
